The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
Simon Cowell's latest video before the Britain's Got Talent 2025 finale has fans convinced he's developing 'Ozempic face' due to his noticeably slimmer features and changed eye shape. Social media erupts with comments from 2023 to 2025, even linking him to Ryan Seacrest's look. Despite the buzz, Cowell tells The Sun he's never tried Ozempic.
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
A pivotal symposium on 'Nutrition in Clinical Practice: From GLP-1 Era to Cardiac Recovery' drew 150 nutrition professionals to Dhaka's KIB Convention Hall. Chaired by renowned dietician Akhtarun Nahar Alo, the event featured keynote speakers from NICVD and BIRDEM, followed by the launch of Nutricaa Limited's OPTIMA meal replacement. This gathering highlights the growing intersection of GLP-1 therapies and targeted nutrition for cardiac recovery.
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
A Hims & Hers Super Bowl ad provocatively claims 'Rich people live longer,' selling telehealth access to GLP-1s, peptides, and testosterone like the elite. But as compounded drugs face DOJ scrutiny, is this democratizing care or risking safety? Dive into the ad, cultural envy, and expert concerns.
Telehealth giant Hims & Hers has abruptly stopped offering its newly launched compounded version of Novo Nordisk's Wegovy pill amid FDA scrutiny. The decision follows constructive industry conversations, raising questions about compounded GLP-1 availability. Patients seeking semaglutide for weight management now face shifting options.
Taiwan's Food and Drug Administration (FDA) has reported 21 cases of suspected adverse reactions to GLP-1 receptor agonists like Ozempic used for weight loss. Symptoms include gastrointestinal disorders, hypoglycemia, nausea, and more. Amid global concerns from US lawsuits and UK pancreatitis warnings, the FDA urges doctor-prescribed use only.
